Normal view

Received — 10 September 2026 ⏭

Molecular Therapy
Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain Subeen Lee · Jaekyung Jeon · Hyunji Lee · Ellane Eda Barcelon · Jinpyo Hong · Sung Joong Lee
Lee and colleagues develop anti-TLR2 nanobodies and scFvs and establish a PLGA-nanoparticle-mediated gene therapy platform for sustained antibody expression. A single intrathecal injection of these PLGA nanoparticles reduces spinal inflammatory responses and provides durable analgesia in a mouse model of neuropathic pain.
29 July 2026 at 08:00

Development of recombinant anti-TLR2 antibodies and PLGA nanoparticle-based gene therapy for the treatment of neuropathic pain

By: Subeen Lee · Jaekyung Jeon · Hyunji Lee · Ellane Eda Barcelon · Jinpyo Hong · Sung Joong Lee

29 July 2026 at 08:00

Lee and colleagues develop anti-TLR2 nanobodies and scFvs and establish a PLGA-nanoparticle-mediated gene therapy platform for sustained antibody expression. A single intrathecal injection of these PLGA nanoparticles reduces spinal inflammatory responses and provides durable analgesia in a mouse model of neuropathic pain.